Impact of AI on Clinical Development

PSI Training Course: Introduction to Machine Learning

This course is aimed at clinical trial statisticians who are new to or with limited experience of machine learning. Attendees will learn about a range of topics in machine learning, including practical sessions in R.

Joint PSI/EFSPI Vaccine SIG Webinar: Statistical and Mechanistic Models for Correlates of Protection

This webinar will explore two different approaches to Correlates of Protection in vaccine development.

Joint PSI/EFSPI Visualisation SIG 'Wonderful Wednesday' Webinars

Our monthly webinar explores examples of innovative data visualisations relevant to our day to day work. Each month a new dataset is provided from a clinical trial or other relevant example, and participants are invited to submit a graphic that communicates interesting and relevant characteristics of the data.

PSI Webinar: Drug Development in Women's Health

The event will open with an overview on drug development in women’s health from a clinician perspective. This talk is followed by talks about statistical challenges when planning IVF studies and analysing the menstrual cycles.

PSI Webinar: Surrogacy

This webinar will provide an overview of surrogacy for licensing and reimbursement. In turn, the need of extensions of the SPIRIT and CONSORT statement will be defined and outlined, with case studies to support.

Joint PSI/EFSPI Pre-Clinical SIG Webinar: Virtual Control Groups in Toxicity Studies

Lea Vaas will present how replacement of concurrent control animals by Virtual Control Groups (VCGs) in systemic toxicity studies may help in contributing to the 3R's principle of animal experimentation: Reduce, Refine, Replace.

Joint PSI/EFSPI Data Science SIG Webinar: Developing Digital Measures (Digital Biomarkers) in Drug Development – insights from Mobilise D consortium

We will share a brief overview of what Mobilise D is and why it is an important step stone in the development of digital biomarkers, and how Mobilise D outputs can be relevant for you.

PSI Career Young Virtual Event (Q2 2024)

This networking event is aimed at statisticians that are new to the pharmaceutical industry who wish to meet colleagues from different companies and backgrounds.

PSI Career Young Virtual Event (Q3 2024)

This networking event is aimed at statisticians that are new to the pharmaceutical industry who wish to meet colleagues from different companies and backgrounds.

PSI Introduction to Industry Training (ITIT) Course - 2024/2025

An introductory course giving an overview of the pharmaceutical industry and the drug development process as a whole, aimed at those with 1-3 years' experience. It comprises of six 2-day sessions covering a range of topics including Research and Development, Toxicology, Data Management and the Role of a CRO, Clinical Trials, Reimbursement, and Marketing.

PSI Career Young Virtual Event (Q4 2024)

This networking event is aimed at statisticians that are new to the pharmaceutical industry who wish to meet colleagues from different companies and backgrounds.

Time	Agenda
09:00 - 09:30	Registration and Coffee
09:30 - 9:45	Welcome Karim Malki, Head, Predictive Analytics, UCB
09:45 - 10:45	Understanding activity patterns through wearable devices and AI algorithms Chris Holmes, Professor of Biostatistics in Genomics in the Nuffield Department of Clinical Medicine and the Department of Statistics, University of Oxford
10:45 - 11:30	Why statisticians should be driving machine learning and AI projects Dr Moira Verbelen, Principal Statistician, UCB
11:30 - 11:45	Break
11:45 – 12:30	The need for data science in the new clinical development paradigm Francis Kendall, Senior Director, Biostatistics and Programming, Cytel
12:30 - 13:30	Lunch and Networking
13:30 - 14:15	Technology Showcase Dr Bhushan Bonde, Head of IT - NewMeds Innovation Development, UCB
14:15 - 15:00	Predicting Crohn's disease risk in asymptomatic relatives Dr Ken Hanscombe, Research Associate at King’s College London
15:00 - 15:15	Coffee Break
15:15 - 16:00	Roche's experience developing Advanced Analytics Communities both internally and externally Chris Harbron, Expert Statistical Scientist, Roche
16:00 – 16:45	Panel Discussion
16:45 – 17:00	Closing Remarks
17:00 – 18:00	Drinks Reception and Networking

UCB	Technology Showcase Abstract: This will be a technical demonstration highlighting some of the latest technology available for performing machine learning and other high intensity computational tasks, including a demonstration of Intel’s portable neural compute stick and a look at how new advances, such as quantum computing, will change the technological landscape.
Chris Holmes (University of Oxford)	Understanding activity patterns through wearable devices and AI algorithms Abstract: New measurement technologies such as wearable devices coupled with AI algorithms, that can learn from large scale streaming data, have the potential for improved evaluation and monitoring of treatment interventions. In this talk we review the prospect for AI to better characterise population activity variation through wearable tech including an analysis of accelerometer data from 100,000 participants in UK BioBank.
Frances Kendall (Cytel)	The need for Data Science in the New Clinical Development Paradigm Abstract: This talk will set the stage on why Data Science is needed to support a New Clinical Development paradigm and what are the drivers of change. It will then put forward an idea on what that Paradigm could look like with examples of work that demonstrate this direction.
Moira Verbelen (UCB)	Why statisticians should be driving machine learning and AI projects Abstract: Advancements in computer science have popularised the widespread use of machine learning and AI. Although methods were mainly developed by computer and data scientists, they are rooted in statistical science. Statisticians are ideally placed to guide the implementation of these ‘new’ approaches in pharma. In-depth understanding of statistical concepts and model fitting are essential skills required to avoid pitfalls such as poor algorithm design, overfitting and incorrect interpretation of results. These considerations and the ensuing value of statisticians’ involvement are even more important in clinical development, where datasets tend to be smaller than those typically used for AI.
Ken Hanscombe (King’s College London)	Predicting Crohn's disease risk in asymptomatic relatives Abstract: An application of elastic net and random forest classifiers to Crohn’s disease (CD) risk in asymptomatic first-degree relatives (FDRs) of CD patients, using multiple environmental and genetic predictors.
Chris Harbron (Roche)	Roche's experience developing Advanced Analytics Communities both internally and externally Abstract: Roche has been successful in building an internal advanced analytics community consisting of over 750 data scientists from across the global Roche organization as well as establishing a number of external advanced analytics partnerships. This talk will discuss how Roche have approached this effort as well highlighting some of the successes and challenges, including crowd sourcing the internal community to tackle key scientific research questions using machine learning.

Event